Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 3/20 | 0.31 |
| ▸ | KDM5C | P41229 | 3/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15994123 | 1.00 | CYP3A4 (0.31) | CYP3A4CYP2D6CYP2C9PRKCQKDM5A | |
| SCHEMBL18831151 | 1.00 | CYP3A4 (0.31) | CYP3A4CYP2D6CYP2C9PRKCQKDM5A | |
| SCHEMBL15994346 | 0.85 | KDM5B (0.35) | CYP3A4CYP2D6CYP2C9PRKCQKDM5A | |
| SCHEMBL20041957 | 0.84 | KDM5A (0.32) | KDM5AKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL16305495 | 0.79 | KDM5B (0.43) | KDM5AKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL17984964 | 0.79 | CYP3A4 (0.33) | CYP3A4CYP2D6KDM5AKDM5CKDM5B | |
| SCHEMBL17984966 | 0.79 | CYP3A4 (0.33) | CYP3A4CYP2D6KDM5AKDM5CKDM5B | |
| SCHEMBL15994045 | 0.79 | CHRM2 (0.36) | CYP3A4CYP2D6KDM5AKDM5CKDM5B | |
| SCHEMBL17984968 | 0.79 | CYP3A4 (0.33) | CYP3A4CYP2D6KDM5AKDM5CKDM5B | |
| SCHEMBL16006935 | 0.79 | CYP3A4 (0.33) | CYP3A4CYP2D6KDM5AKDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | CYP3A4 2124/4885CYP2D6 1643/4885CYP2C9 1969/4885 |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | CYP3A4 2124/4885CYP2D6 1643/4885CYP2C9 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.